-
EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)
▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...Nov. 09. 2021 -
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion
▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...Oct. 28. 2021 -
EOFlow and Sinocare Establish a Joint Venture Company
▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...Oct. 27. 2021 -
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea
▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...Oct. 14. 2021 -
EOFlow Completes its First Shipment to Europe
▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...Sep. 30. 2021 -
[Financial News] EOFlow plans to start launching in Europe this fall
Financial News released a CEO interview article today on page 30 of the Financial Newspaper, and online yesterday (In Korean only: https://www.fnnews.com/news/202107011340009046). "EOFlow will start launching in Europe this fall. We're preparing to make entrance into the U.S. market," Jesse Kim, CEO of EOFlow, said. During the interview with reporter Seo Hye-jin, Jesse Kim showed confidence in the wearable insulin pump "EOPatch," which EOFlow successfully commercialized for the second time in the world after Insul...Jul. 02. 2021 -
EOFlow Expands EOPump Production Capacity
▶ Preemptive investment decision to handle growing domestic and foreign demand… Expecting external growth ▶ Contract for the site and the manufacturing facility of the core component is scheduled... Trial production is scheduled for September EOFlow (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announced that it will sign a contract to buy a manufacturing facility. The new facility is located on a 5,967㎡ site in Gwangju, Gyeonggi-do in South Korea. The purchase price will be $5...Jun. 15. 2021 -
EOFlow Receives CE Mark for its Innovative Wearable Insulin Pump
▶ Wearable Insulin patch, controller ‘ADM’ and smartphone app ‘Narsha’ receive CE MDD ▶ EOFlow targets foreign markets and plans to launch in European market in 2H21 EOFlow lays the foundation for its entry into overseas markets by acquiring CE Mark. After its recent full launch in South Korea, EOFlow now plans to target international markets in earnest. On May 25, EOFlow, a provider of wearable drug delivery solutions, has announced that it received CE Mark from the European Union (EU) to commercialize its weara...May. 25. 2021 -
EOFlow Receives International Standard Information/Privacy Security Management Certification
On May 3, EOFlow announced that it received international standard information security management certification ‘ISO 27001’ and privacy information management certification ‘ISO 27701’. It was the first time in the Korean medical device industry that a company received 'ISO 27001' and 'ISO 27701' certifications at the same time. By acquiring these certifications, EOFlow proved its highest level of security in the digital healthcare industry where information and privacy protection is critical.&...May. 03. 2021 -
Medical Device Startup Nephria Bio to Use Drexel's MXene Filter Materials in Wearable Artificial Kidney Technology
https://drexel.edu/now/archive/2021/April/MXene-NephriaBio-wearable-artificial-kidney/ Drexel University’s MXene material is one step closer to transforming the lives of people suffering from end-stage kidney disease. Nephria Bio, Inc., a U.S.-based spin-off of the South Korean medical device company EOFlow Co., Ltd., has signed a licensing agreement with the University to use the two-dimensional material, discovered at Drexel, as a filter in a wearable artificial kidney device it is developing. The technology could allow many of t...Apr. 29. 2021 -
EOFlow’s US Subsidiary Nephria Gets License on New "MXene" Nanomaterial from Drexel University… Marking a Big Step in Development of a Wearable Artificial Kidney
▶ Secured a key technology needed to develop wearable artificial kidneys (WAK) ▶ Completes core technology line-up needed to develop WAK On April 29, EOFlow, a provider of wearable drug delivery solutions, announced that its U.S. subsidiary Nephria Bio, Inc. (Nephria) signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials. Through this license agreement, Nephria secured the exclusive rights to use the new MXene nanomaterial owned by Drexel University in the dialysis field. Nephria plans...Apr. 29. 2021 -
[Hankyung BIO Insight] EOFlow Plans for Diversification to Non-insulin Drug Delivery
EOFlow's product diversification plan was introduced on Hankyung BIO Insight on 04/25/2021 (in Korean only): https://www.hankyung.com/society/article/2021042537721 In summary, reporter Sun-a Lee from Bio & Healthcare department in the Korea Economic Daily announced that EOFlow plans to leverage advantages of its recently launched wearable insulin pump EOPatch and expand the business to other non-insulin drug delivery. The advantages of its core platform technology include small, light, low-power, high-output and low-cost EOPump, ...Apr. 26. 2021 -
[Hankyung BIO Insight] EOPatch's CE audit is scheduled for this month…plans to launch in Europe in 2H21
EOFlow's EOPatch CE surveillance audit plan was introduced on Hankyung BIO Insight on 04/07/2021 (in Korean only): https://www.hankyung.com/it/article/202104078094i In summary, Reporter Yena Kim explained that EOPatch's CE surveillance audit is scheduled from April 20 and following the CE MDD marking by the end of May, Europe launch is expected in 2H21. EOFlow's wearable, disposable insulin patch will be distributed in the European market by Menarini, under its brand. Reporter emphasized that EOPatch will be able to sec...Apr. 15. 2021 -
[MoneyToday] EOFlow Aims for the Global No.1 with its Wearable Artificial Pancreas Solution
EOFlow's wearable insulin pump "EOPatch" and its wearable artificial pancreas solution was introduced on MoneyToday on 04/13/2021 (in Korean only): https://news.mt.co.kr/mtview.php?no=2021041218010214599&type=1 In summary, Reporter Kim emphasized that EOFlow is leading the paradigm shift in insulin delivery, starting with EOPatch. EOFlow's recently launched EOPatch is a disposable wearable insulin pump which is used to continuously deliver insulin in blood glucose control. It is the world’s seco...Apr. 13. 2021 -
EOFlow Presented a Drug Delivery Session at 2021 Spring Symposium of Korean Endocrine Society
▶ Delivers a paradigm shift in diabetes management with its wearable insulin pump “EOPatch” ▶ Leading digital medical device trends with EOFlow’s innovative technology On April 12, EOFlow, a provider of wearable drug delivery solutions, has announced that it presented a drug delivery session at spring symposium of Korean Endocrine Society. 2021 Spring Symposium of KES themed “Endocrinology Meets Immunology” was held at Yeosu EXPO Convention Center from April 9th to 10th, where medical experts in the field o...Apr. 12. 2021
Healthcare Innovation Park #H2202 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
